Immunohistochemical assessment of HER2 expression in gastric cancer in a cohort of 118 Brazilian patients

Jung, Juliana Elizabeth; Ioshii, Sérgio Ossamu

doi:10.1590/s1676-24442013000500010

Cited by 6 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Association of HER2 positivity with histological grade and presence of lymphovascular invasion has also been reported by some authors [ 19 , 25 , 31 , 46 ] but not by others [ 20 , 47 ]. A recent meta-analysis comprising 15 studies and 5,290 patients concluded that not only Laurén’s classification system but also tumor differentiation and lymphovascular invasion were associated with HER2 positivy [ 48 ].…”

Section: Discussionmentioning

confidence: 61%

“…In more recent research using specific HER2 scoring criteria for GC, IHC 3+ cases ranged from 0.8 % to 11.6 % [ 19 – 22 , 25 , 26 ]. Studies showing the lowest rates (0.8 %, 3 % and 6 %) used tumor tissue microarrays (TMAs) obtained from surgical specimens and other anti-HER2 antibodies rather than 4B5 [ 19 , 20 , 22 ]. These results are difficult to be compared with ours due to methodological differences, especially when TMAs and tumoral protein expression heterogeneity are confronted.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections

Laboissiere

Buzelin²,

Balabram³

et al. 2015

BMC Gastroenterol

View full text Add to dashboard Cite

BackgroundGastric cancer is usually diagnosed in an advanced stage of disease and treatment options are sparse. Trastuzumab was recently approved for metastatic or locally advanced carcinomas arising in the stomach or in the gastroesophageal junction in patients with HER2-positive tumors. However, data on the frequency of HER2-positive cases among Brazilian patients are limited. Our aim was to characterize HER2 protein and gene status in a series of Brazilian patients with gastric cancer and to evaluate its association with clinicopathological data.MethodsHistological slides from 124 primary gastrectomies were reviewed and their pathological reports were retrieved from the files at a Brazilian university hospital. Automated immunohistochemistry for HER2 was performed on whole-tissue sections from each tumor. HER2-equivocal cases by immunohistochemistry were submitted to automated dual in situ hybridization for gene amplification evaluation. HER2 status was confronted with clinicopathological parameters in order to assess statistically significant associations.ResultsImmunohistochemistry analysis revealed that 13/124 cases (10.5 %) were HER2 positive (3+), 10/124 cases (8.1 %) were equivocal (2+) and 101/124 cases (81.4 %) were negative, being 7 cases 1+. None of the equivocal cases showed gene amplification. The overall HER2 positivity rate was 10.5 %. There was an association between HER2 expression and Laurén’s intestinal histological subtype (P = 0.048), well to moderately differentiated tumors (P = 0.004) and presence of lymphovascular invasion (P = 0.031). No association was found between HER2 status and tumor topography.ConclusionsConfronted with data published by other authors, the lower percentage of HER2-positive cases found in our series might be partially explained by the lower frequency of tumors arising at the gastroesophageal junction in comparison with distal gastric carcinomas in Brazilian patients. This could also account for the lack of statistically significant association between HER2 status and tumor topography in our study.

show abstract

Section: Discussionmentioning

confidence: 61%

Section: Discussionmentioning

confidence: 99%

Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections

Laboissiere

Buzelin²,

Balabram³

et al. 2015

BMC Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Her-2 gene is an oncogene, located in human chromosome 17q21, which encodes a cell membrane glycoprotein with tyrosine kinase activity, belonging to the tyrosine kinase type I receptor family, and participates in cell division, growth, reproductive regulation, and relates with the cell motility, enhancement of cell viability, and metastasis of cancer cells. [12][13][14][15] It is inactive under normal circumstances; when it is affected by carcinogenic factors, its structure or expression is out of control and active, and, in turn, features with tumor transformation activity which induces malignant transformation of cells. The high expression of Her-2 has been found in a variety of tumors, such as colorectal cancer, bladder cancer, and ovarian cancer.…”

Section: Discussionmentioning

confidence: 99%

The expression and clinical significance of PDCD4 and Her-2 in human gastric cancer

Yang

Jiang

Liu³

et al. 2019

Eur J Inflamm

View full text Add to dashboard Cite

To investigate the correlation and clinical significance between programmed cell death factor 4 (PDCD4) and epidermal growth factor receptor 2 (Her-2) expressions and clinicopathological parameters in patients with gastric cancer, a total of 65 cases of gastric cancer and the corresponding normal mucosa with PDCD4 and Her-2 protein expressions were detected by SP immunohistochemical staining, and 50 cases of gastric cancer and the corresponding normal mucosa with PDCD4 and Her-2 protein expression quantities were detected by Western blot, in order to analyze the relationship between the positive expressions of PDCD4 and Her-2 protein and the clinicopathological features of patients with gastric cancer. The results showed that the positive rate of PDCD4 protein expression in gastric cancer tissues was 7.7%, which was significantly lower than that in the corresponding normal tissues, that is, 77.5% (P < 0.05); the positive rate of Her-2 expression was 41.5%, which was significantly higher than that of the corresponding normal tissues, which is 2.5% (P < 0.05). The Western blot test showed that the expression of PDCD4 protein in gastric cancer was 0.3105 ± 0.0073, which was significantly lower than that in the corresponding normal tissues, that is, 0.9428 ± 0.0127 (P < 0.05); the expression level of Her-2 protein in gastric cancer tissues was 0.9428 ± 0.0127, which was significantly higher than that of the corresponding normal mucosa, which is 0.2054 ± 0.0264 (P < 0.05). The positive expressions of PDCD4 (5/65) and Her-2 (27/65) were significantly correlated with the differentiation degrees and TNM stages of gastric cancer (P < 0.05). However, no significant correlation can be observed from Table 2 (P > 0.05), regarding sex, age, tumor size, and lymph node metastasis. Our research claimed that PDCD4 and Her-2 may play an important role in the invasion and metastasis of gastric cancer, which has a negative correlation with biological behaviors of gastric cancer. The low expression of PDCD4 and the high expression of Her-2 in gastric cancer may promote the occurrence and progression of cancer. The PDCD4 and Her-2 test can be used as an index to evaluate the malignant biological behaviors of gastric cancer and prognosis, and provide a theoretical basis for targeted therapy.

show abstract

“…6 The HER2/neu protein is 185-kDa transmembrane Tyrosine Kinase (TK) receptor and a member of the Epidermal Growth Factor Receptors (EGFRs) family which can influence cell proliferation, apoptosis, adhesion, migration, and differentiation. 4,7 HER2/neu is encoded by a gene located on chromosome 17q21. In carcinomas, HER2/neu acts as an oncogene, mainly because high-level amplification of the gene induces protein overexpression in the cellular membrane and subsequent acquisition of advantageous properties for a malignant cell.…”

mentioning

confidence: 99%

HER2/neu immunohistochemical expression in gastric carcinoma

Sadanandan¹,

Arunraj²

2020

Int J Res Med Sci

View full text Add to dashboard Cite

Background: Gastric carcinoma is a deadly disease with high mortality. A better understanding of the molecular basis of gastric cancer has contributed to the development of rationally designed molecular targeted therapies which will improve the survival rate. A genetic alteration that could help in targeted therapy and prognostication includes Human Epidermal Growth Factor Receptor 2 (HER2/neu) overexpression in gastric carcinoma. The objective of the present study was to identify and evaluate the HER2/neu protein immunohistochemical expression in gastric cancer from biopsies and surgical resection specimens and to evaluate their correlation with histopathological features.Methods: Total/subtotal gastrectomy specimens and gastric biopsies from a tertiary care center in South India were included in the study and assessed by light microscopy and Immunohistochemistry (IHC).Results: HER2/neu overexpression was seen in 28.6% of gastric adenocarcinoma. HER2/neu overexpression was seen in 44.2% of intestinal-type and 20% of mixed type with none of the diffuse type exhibited HER2/neu positivity and this was statistically highly significant with p value of <0.01. HER2/neu positivity was found in 50% well-differentiated and 36.4% moderately differentiated tumors with none of the poorly differentiated tumors exhibiting HER2/neu positivity and this was statistically highly significant with p value of <0.01.Conclusions: This study highlights the importance of the identification of HER2/neu overexpression in gastric adenocarcinoma. This will help in prognostication and identifying patients suitable for novel therapeutic interventions which will help in prolongation of survival of patients with this deadly disease.

show abstract

Immunohistochemical assessment of HER2 expression in gastric cancer in a cohort of 118 Brazilian patients

Cited by 6 publications

References 26 publications

Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections

Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections

The expression and clinical significance of PDCD4 and Her-2 in human gastric cancer

HER2/neu immunohistochemical expression in gastric carcinoma

Contact Info

Product

Resources

About